USA In recent years, the United States cell and gene therapy (CGT) landscape has undergone a profound transformation. The sector turned a historic corner with the groundbreaking 2023 approvals of Casgevy and Lyfgenia for sickle cell disease – Casgevy being the world’s first CRISPR-based gene therapy – establishing genomic editing as…
USA Cell and gene therapies (CGTs) can now cure diseases that were untreatable a decade ago, often with a single dose. Yet most eligible patients – even those in rich countries like the United States – will never receive them. In many cases, the science is already in place. However, high…
USA Thomas Madden is the CEO of Acuitas Therapeutics, the lipid nanoparticle delivery technology company whose platforms underpinned some of the most significant advances in mRNA medicine, such as the COVID-19 vaccines. In this interview, Madden shares how the company is evolving beyond COVID. He discusses the company’s preformed vesicle technology…
Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. pharmaboardroom · The bright future of…
Vaccines The story of how British doctor Edward Jenner serendipitously discovered a way to inoculate people against smallpox in 1976 by injecting them with cowpox pus is well-known. Over the past two centuries, vaccine development platforms have (thankfully) advanced leaps and bounds, delivering a wealth of options to tackle global health…
Global Dr Thomas D. Madden, CEO and founder of Acuitas Therapeutics, shares the story behind their involvement in Pfizer and BioNTech’s COVID-19 vaccine, the numerous applications of the company’s proprietary lipid nanoparticle (LNP) delivery technology, as well as the growth strategy of the Canadian company. We quickly recognized that the…
See our Cookie Privacy Policy Here